Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-010848
Filing Date
2025-08-08
Accepted
2025-08-08 07:30:27
Documents
92
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ymab-20250630x10q.htm   iXBRL 10-Q 2432675
2 EX-31.1 ymab-20250630xex31d1.htm EX-31.1 15493
3 EX-31.2 ymab-20250630xex31d2.htm EX-31.2 15501
4 EX-32.1 ymab-20250630xex32d1.htm EX-32.1 7728
5 EX-32.2 ymab-20250630xex32d2.htm EX-32.2 7755
  Complete submission text file 0001558370-25-010848.txt   11317107

Data Files

Seq Description Document Type Size
6 EX-101.SCH ymab-20250630.xsd EX-101.SCH 68750
7 EX-101.CAL ymab-20250630_cal.xml EX-101.CAL 57562
8 EX-101.DEF ymab-20250630_def.xml EX-101.DEF 293359
9 EX-101.LAB ymab-20250630_lab.xml EX-101.LAB 557221
10 EX-101.PRE ymab-20250630_pre.xml EX-101.PRE 478708
95 EXTRACTED XBRL INSTANCE DOCUMENT ymab-20250630x10q_htm.xml XML 2523634
Mailing Address 202 CARNEGIE CENTER SUITE 301 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 301 PRINCETON NJ 08540 646-885-8505
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

EIN.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38650 | Film No.: 251196200
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)